首页>投融资
瑞风生物
PreB轮
瑞风生物是中国头部的基因编辑药物创新企业，以基因编辑技术为核心驱动，致力于革新性药物的诞生。瑞风生物是国际上早期应用基因编辑探索遗传疾病治疗的高水平团队，并持续在血液科、眼科等疾病方向积累了开创性成果，在包括基因编辑工具创新、成药策略发现、新型动物模型构建、多层次药效和安全性评估等层面具备了高水平的技术积累，拥有体内和体外两大创新药物方向。瑞风生物的使命是基于革新性的基因技术，为严重疾病患者提供可及性和治愈性药物。目前在遗传病、复杂疾病和肿瘤领域等皆有管线布局，其中β-地中海贫血基因编辑疗法已经取得全球先进水平的临床进展。
基本信息
-
公司全称广州瑞风生物科技有限公司
-
类型基因药物研发商
-
产业领域药品研发/制造、生物药
-
公司人数101~500人
-
地址广州市黄埔区瑞和路39号H6栋131-150、H6栋231-250、H7栋101-120、H7栋201-220
-
联系电话020-31702930
-
邮箱wlu@reforgene.com
-
成立时间2019-01-17
投融资
-
2023-04-28PreB轮数亿人民币国聚创业投资博远资本新兴基金雅惠投资广州越秀产业基金善沣基金宁波元因创投港粤资本光大控股
-
2023-04-28PreB轮数亿人民币博远资本国聚创投新兴基金港粤资本雅惠投资越秀产业基金光大控股善沣基金宁波元因创投
-
2021-09-16A+轮数亿人民币招商证券元生创投博远资本创新工场光大控股
-
2021-09-16A+轮数亿人民币元生创投创新工场博远资本招商证券光大控股高瓴资本博时基金
-
2020-11-02A轮近亿人民币雅惠投资联想之星
-
2020-11-02A轮近亿人民币雅惠投资联想之星苇渡创投
-
2020-01-19战略融资未透露联想控股
-
2020-01-19天使轮未透露联想之星联想控股
-
2019-01-01战略融资未透露联想之星
-
2019-01-01战略投资未透露联想之星
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息